Amylin rated at neutral by Merrill

Merrill Lynch analyst Tom McGahren rated Amylin Pharmaceuticals Inc. at neutral as Byetta sales track modestly below Merrill's estimate of $125 million but roughly in line with Street consensus of $118 million with one week of NDC data remaining for the third quarter. New Byetta prescriptions for the week ended Sept. 22 were flat at 22,593, compared with the prior week. Overall, NDC data for total weekly Byetta sales are averaging $10.8 million in September compared with $10.1 million in August. Shares of the San Diego-based biopharmaceutical company were down $1.55, or 3.52%, at $42.52. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.